'A crucial step on our journey to net zero': Northern Ireland pharma leader increases clean power usage through local wind farm partnership
Almac Group joins NTR to increase clean electricity offtake by over 20% from Murley Wind Farm, supporting site expansion and carbon reduction goals
Dublin-based infrastructure investor NTR and Northern Ireland pharmaceutical services group Almac Group have agreed to increase the volume of clean electricity supplied from Murley Wind Farm, two years into their successful corporate Power Purchase Agreement (PPA) partnership.
Murley Wind Farm, which began operations in 2024, initially supplied just under 50% of its output to Almac under the original PPA. Following continued success and the expansion of Almac’s operations in Northern Ireland, the companies have agreed to increase the contracted volume to just under 70% of the wind farm’s output.
This additional renewable energy will significantly reduce carbon emissions from electricity used at Almac’s Craigavon headquarters, supporting both the company’s growth and its goal to cut Scope 1 and 2 emissions by 50% by 2030. The Craigavon campus currently employs over 4,000 of Almac’s 7,800 global workforce.
Francisco Del Rio, head of Power Sales Europe at NTR, said: “This is a great example of partners growing together, whereby we are able to meet Almac’s need for additional clean power from a local source as they expand operations.
"Across our different markets in Europe, we are increasingly working with partners around bespoke PPAs according to their requirements, be they locational or requirements to shape power supply around their load and it’s this type of flexibility that differentiates NTR.”
Niall Harkin, executive director, Almac Group, added: “We are delighted to increase our clean power volume which allows us to continue to power almost all operations at our Craigavon site as it expands, with fully certified renewable energy.
“Almac’s participation in this project has been a crucial step on our journey to net zero and helps to significantly reduce carbon emissions from the electricity we consume. “As a global leader in providing a range of expert services and support across the drug development lifecycle, it is crucial that we continue to demonstrate our commitment to the long-term sustainability goals of the sector. I am hugely encouraged by the progress that we are making on our climate journey.”